BVS
Bioventus Inc
13.60$
-0.3%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 0.0% | -2.1% | -0.3% | -2.9% | -5.4% | -5.0% | +2.2% | -0.7% | -2.6% | -4.8% | +3.5% | |
| – | +7.4% | -0.8% | +16.2% | -3.3% | -7.7% | -9.5% | +10.4% | +2.1% | -2.9% | -8.4% | +3.1% | |
| – | +37.8% | -31.9% | +27.1% | +34.6% | -3.5% | -45.2% | +44.3% | +28.1% | +21.5% | -30.0% | -17.8% | |
| – | +37.8% | -31.9% | +27.1% | +34.6% | -3.5% | -45.2% | +44.3% | +28.1% | +21.5% | -30.0% | -17.8% | |
| – | +8.8% | +2.2% | +9.4% | -11.2% | +4.5% | -7.3% | +12.1% | -1.5% | -1.6% | -6.1% | +14.8% | |
| – | -6.4% | +6.2% | -9.7% | +2.8% | +2.7% | +1.7% | +2.6% | -0.2% | -14.6% | +1.2% | -4.1% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -2.2% | -2.4% | -9.8% | -2.3% | -2.4% | -2.2% | -2.2% | -2.5% | -2.4% | -2.4% | -2.4% | |
| – | +0.9% | -2.2% | +4.6% | -3.4% | -6.9% | -6.7% | -0.1% | -2.2% | -7.9% | -8.5% | -4.9% | |
| – | +9.1% | -1.2% | +33.5% | -8.6% | -0.5% | -16.9% | +6.3% | -12.9% | -0.8% | -7.7% | +2.9% | |
| – | +42.2% | +28.6% | +7.7% | +0.0% | -29.1% | +36.6% | +16.1% | -74.1% | +70.8% | -2.4% | +22.1% | |
| – | +30.6% | -17.1% | +27.9% | -31.1% | +40.6% | -19.0% | +26.3% | +9.9% | -59.0% | +120.1% | -16.0% | |
| – | -2.1% | -3.2% | -3.0% | +0.1% | -10.6% | +0.1% | -3.5% | +4.5% | -10.4% | -9.2% | -9.3% | |
| – | -2.2% | -1.3% | -11.9% | -1.5% | -0.5% | +0.1% | +8.8% | +3.0% | +10.8% | +2.6% | +20.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.3% | +0.6% | +1.1% | +1.9% | +0.3% | +0.9% | +3.8% | +0.4% | +0.1% | +1.6% | +1.2% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.